Several other equities analysts have also issued reports on IRWD. Cowen set a $12.00 price target on Ironwood Pharmaceuticals and gave the stock a hold rating in a research report on Friday, September 13th. ValuEngine downgraded Ironwood Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, November 1st. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $14.50.
Ironwood Pharmaceuticals stock opened at $12.48 on Friday. The firm has a fifty day simple moving average of $10.86 and a two-hundred day simple moving average of $10.19. Ironwood Pharmaceuticals has a twelve month low of $7.91 and a twelve month high of $15.21. The company has a market capitalization of $1.96 billion, a PE ratio of -13.14 and a beta of 1.87.
Several institutional investors have recently bought and sold shares of IRWD. Amundi Pioneer Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at $63,000. Diamond Hill Capital Management Inc. bought a new position in Ironwood Pharmaceuticals in the second quarter worth about $115,000. Signition LP bought a new position in Ironwood Pharmaceuticals in the third quarter worth about $100,000. Russell Investments Group Ltd. purchased a new stake in Ironwood Pharmaceuticals in the second quarter worth about $135,000. Finally, Prudential Financial Inc. lifted its holdings in Ironwood Pharmaceuticals by 9.6% in the second quarter. Prudential Financial Inc. now owns 14,124 shares of the biotechnology company’s stock worth $155,000 after buying an additional 1,240 shares during the period.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Recommended Story: Accumulation/Distribution
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.